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Antiphospholipid 
Syndrome and 
Acute HIV Infection
To the Editor: Patients with acute 
HIV infection frequently experience a 
syndrome characterized by fever, sore 
throat, lymphadenopathy, maculopap-
ular rash, and lymphomonocytosis, 
which mimics acute infectious mono-
nucleosis, 3–6 weeks after primary 
infection (1). Aseptic meningitis, en-
cephalitis, and peripheral neuropa-
thy are the most commonly observed 
features. In contrast, antiphospholipid 
syndrome complicated with pulmo-
nary emboli is not commonly associ-
ated with acute retroviral syndrome. 
The following case should prompt cli-
nicians to consider an expanded clini-
cal scope of initial signs and symp-
toms for acute HIV infection.
A 28-year-old homosexual man 
was admitted to a hospital in Madrid, 
Spain, on June 22, 2009, with fever, 
pharyingitis, and myalgias. General-
ized lymphadenopathy was found on 
examination. Lymphomonocytosis and 
mild elevation of serum aspartate ami-
notransferase and serum alanine amin-
otransferase levels were found. Chest 
radiographs showed no abnormalities. 
Results of a commercial ELISA for 
HIV-1 and HIV-2 were negative. Re-
sults of a p24 antigen-capture assay 
were positive, and viral load measured 
by reverse transcription–PCR (RT-
PCR, Amplicor; Roche Molecular 
Diagnostics, Pleasanton, CA, USA) 
was 2,600,000 copies RNA HIV/mL. 
CD4+ T-cell count was 297 cells/μL.
The patient was discharged with 
instructions to take acetaminophen, 
but he was readmitted 1 week later 
with recurring fever, pleuritic chest 
pain, and shortness of breath. He was 
febrile (38.5ºC), tachycardic, and 
tachypneic and had a blood pressure 
of 155/72 mm Hg and generalized 
lymphadenopathy. Blood tests showed 
a hemoglobin level of 10.6 g/dL, leu-
kocyte count of 5,160 cells/μL, and 
thrombocyte count of 293 cells/μL. 
Results of renal function tests were 
within normal limits as were serum 
aminotransferase levels. Lactate dehy-
drogenase level was 698 IU/L (refer-
ence range 211–423 IU/L) and D-di-
mer was 3,414 μg/L (reference range 
68–494 IU/L). Fibrinogen levels, pro-
thrombin time, and partial thrombo-
plastin time were normal. Chest radio-
graphs showed a small area of pleural 
effusion on the left side. A computed 
tomographic scan of the chest showed 
multiple pulmonary emboli with areas 
of parenchymal infarction.
Antibodies against phospholipids 
(PLs) and β2-glycoprotein I (β2GPI) 
measured by ELISA were detected at 
high titers: immunoglobulin (Ig) M 
anticardiolipin + 72 U MPL/mL (posi-
tive at >20 U MPL/mL), IgG anticar-
diolipin + 158 U GLP/mL (positive 
at >20 U GLP/mL), IgG anti-β2GPI + 
210 U/mL (positive at >10). Results of 
screening tests for thrombophilia and 
other autoantibodies were within nor-
mal limits.
The patient was treated with low 
molecular weight heparin, oxygen, and 
analgesics. His fever subsided, and he 
was discharged a few days later while 
continuing to receive acenocoumarol, 
an oral coumarin anticoagulant. Re-
sults of a repeated HIV ELISA were 
then positive. Western blot assay con-
ﬁ  rmed the presence of antibodies to 
p24, gp41, and gp120/160.
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One month after discharge, the 
patient was doing well. Titers of PL 
antibodies had declined (IgM anti-
cardiolipin, negative; IgG anticardio-
lipin, 54; IgG antibody against β2GPI 
90). Viral load was 762,000 copies 
of HIV-1 RNA/mL, and CD4+ T-cell 
count was 320 cells/μL. At follow-
up, 2 months after symptom onset, he 
was asymptomatic, and PL antibody 
titers continued to decline; antibodies 
against β2GPI were undetectable, and 
only IgG anticardiolipin was still de-
tected at lower titers (+33). Viral load 
was 129,000 copies/mL, and CD4+ 
lymphopenia was slowly improving 
(408 cells/μL). He was receiving an-
ticoagulant therapy but not antiretro-
viral drugs.
Antibodies against PLs have been 
commonly found in patients with au-
toimmune diseases such as systemic 
lupus erythematosus and primary an-
tiphospholipid syndrome, in which 
clinical manifestations (mainly throm-
botic events) have been directly at-
tributed to antibodies against PLs. In 
these patients, antibodies against PLs 
are speciﬁ  c for a neoepitope consti-
tuted by the union of β2GPI, a lipid-
binding coagulation inhibitor, to the 
cellular membrane phospholipids (2). 
In addition, these antibodies have 
been observed in some acute viral and 
bacterial infections as a manifestation 
of the intense antigenic stimulation of 
the immune system. These antibodies 
recognize lipid components of cellu-
lar membrane and have no direct role 
in the coagulation pathway, and their 
presence probably reﬂ  ects  intense 
antigenic stimulation of the immune 
system. Because of the lack of a sta-
tistical association between these anti-
bodies and development of thrombotic 
events, the presence of these antibod-
ies is thought to be an epiphenomenon 
and of no clinical relevance (3,4).
Anticardiolipin antibodies and, 
less frequently, β2GPI antibodies 
also have been found in patients with 
chronic HIV infection, but their as-
sociation with thrombotic events has 
not been proven (5). However, cases 
of antiphospholipid syndrome in HIV-
infected patients have been anecdot-
ally reported, prompting clinicians to 
reconsider the real role of these anti-
bodies, particularly B2GPI antibodies, 
which are thought to be more speciﬁ  c 
for antiphospholipid syndrome. Avas-
cular bone and cutaneous necrosis and 
deep vein thrombosis and pulmonary 
emboli were the most common mani-
festations of antiphospholipid syn-
drome (6–8).
In HIV-infected patients, PL anti-
bodies and β2GPI antibodies have been 
strongly linked with level of viral rep-
lication (9). In our patient, the levels of 
viral load and PL antibodies seemed 
to run in parallel, with high concentra-
tions of both at hospital admission and 
simultaneous decline over time. This 
observation suggests that patients with 
high levels of viremia, such as those 
with acute retroviral infection, could be 
at risk for high titers of PL antibodies 
and thrombotic events. Testing for anti-
bodies in these patients should be con-
sidered as part of routine examination.
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